Moderna Stock Is Rising. A New Covid Vaccine Is Coming for Some People. - Barron's
1. FDA approved mNEXSPIKE for high-risk adults aged 65 and up. 2. Approval relieves some concerns amid policy changes under Kennedy's leadership. 3. Moderna's shares rose 4.1% despite an overall 82% decline in the past year. 4. Kennedy's department has withdrawn nearly $600 million in funding for Moderna. 5. mNEXSPIKE targets Covid-19, critical amidst over 47,000 deaths last year.